Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) Other Non Operating Income (2018 - 2025)

Regenxbio (RGNX) has 11 years of Other Non Operating Income data on record, last reported at $18000.0 in Q4 2025.

  • For Q4 2025, Other Non Operating Income fell 78.31% year-over-year to $18000.0; the TTM value through Dec 2025 reached $83000.0, down 52.3%, while the annual FY2025 figure was $83000.0, 52.3% down from the prior year.
  • Other Non Operating Income reached $18000.0 in Q4 2025 per RGNX's latest filing, down from $19000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $554000.0 in Q2 2021 and bottomed at -$141000.0 in Q4 2023.
  • Average Other Non Operating Income over 5 years is $67150.0, with a median of $33000.0 recorded in 2021.
  • Peak YoY movement for Other Non Operating Income: skyrocketed 305.26% in 2022, then tumbled 283.12% in 2023.
  • A 5-year view of Other Non Operating Income shows it stood at $19000.0 in 2021, then soared by 305.26% to $77000.0 in 2022, then crashed by 283.12% to -$141000.0 in 2023, then skyrocketed by 158.87% to $83000.0 in 2024, then crashed by 78.31% to $18000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non Operating Income were $18000.0 in Q4 2025, $19000.0 in Q3 2025, and $21000.0 in Q2 2025.